Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives.</li><li> The technology involved also has the potential to more efficiently get other treatments to the needed area.</li><li> The company has conducted preclinical testing that has shown dramatic results and has been awarded an important FDA designation.</li></ul>

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives. The technology involved also has the potential to more efficiently get other treatments to the needed area. The company has conducted preclinical testing that has shown dramatic results and has been awarded an important FDA designation.

NRXBF:  Initiating Coverage: Potential Breakthrough Treatment for Spinal Injuries

Nurexone Biologic

NRXBF: Initiating Coverage: Potential Breakthrough Treatment for Spinal Injuries